Novo Nordisk Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVO NORDISK, and what generic alternatives to NOVO NORDISK drugs are available?
NOVO NORDISK has five approved drugs.
There are four US patents protecting NOVO NORDISK drugs.
There are eighty-three patent family members on NOVO NORDISK drugs in twenty-nine countries and one hundred and one supplementary protection certificates in sixteen countries.
Summary for Novo Nordisk
| International Patents: | 83 |
| US Patents: | 4 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
| Patent Litigation for Novo Nordisk: | See patent lawsuits for Novo Nordisk |
Drugs and US Patents for Novo Nordisk
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | INNOFEM | estradiol | TABLET;ORAL | 040312-003 | Nov 19, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Novo Nordisk Inc | INNOFEM | estradiol | TABLET;ORAL | 040312-002 | Nov 19, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Novo Nordisk Inc | INNOFEM | estradiol | TABLET;ORAL | 040312-001 | Nov 19, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novo Nordisk
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,004,297 | ⤷ Sign Up |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,458,924 | ⤷ Sign Up |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RE43834 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVO NORDISK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
| ➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
| ➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
International Patents for Novo Nordisk Drugs
Supplementary Protection Certificates for Novo Nordisk Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2861072 | 2024C/512 | Belgium | ⤷ Sign Up | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406 |
| 0398460 | C300221 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
| 1214076 | SZ 49/2008 | Austria | ⤷ Sign Up | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
